What did we find?

Blood glucose was reduced more with iGlarLixi than iGlar and a greater proportion of participants reached blood glucose targets.

![Graph showing people reaching their target blood glucose (HbA1c <7 %)]

- **iGlarLixi**: 63%
- **iGlar**: 30%

Common side effects of insulin-based medicines include weight gain and a risk of blood glucose levels becoming too low, while some people taking Lixi have digestive system side effects.

- Participants on iGlarLixi did not gain weight, unlike those on iGlar.
- There was no increased chance of experiencing low blood glucose with iGlarLixi than with iGlar.
- In line with previous studies, more participants had digestive system side effects with iGlarLixi than with iGlar, but none were serious.

What does this mean?

iGlarLixi controls blood glucose better than iGlar in Chinese adults with type 2 diabetes while also allowing them to avoid weight gain and had an overall low risk of side effects.